⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385886 | 0.81 | — | — | |
| SCHEMBL12385885 | 0.81 | — | — | |
| SCHEMBL12385879 | 0.81 | — | — | |
| SCHEMBL3438572 | 0.78 | THRB (0.42) | — | |
| SCHEMBL8163463 | 0.77 | MAPT (0.40) | — | |
| SCHEMBL337579 | 0.75 | PRKACA (0.33) | — | |
| SCHEMBL27828477 | 0.72 | NLRP3 (0.42) | — | |
| SCHEMBL22072941 | 0.70 | — | — | |
| SCHEMBL10196068 | 0.70 | — | — | |
| SCHEMBL10196198 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624033-B2 | KRAS inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125398-A1 | 5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735440-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250250271-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250154148-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-15 | — | — | US | disclosed |
| WO-2025016391-A1 | THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF | 南京再明医药有限公司 | 2025-01-23 | — | — | WO | disclosed |
| WO-2025006967-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006962-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024217523-A1 | SELECTIVE TKY2 INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) | 2024-10-24 | — | — | WO | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-7825155-B2 | Oxindole derivative as feeding control agent | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| WO-2008119720-A1 | 1-(1-CYCLOBUTYL-4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |